Cas:7379-84-2 1,4-BIS(2-CHLOROETHYL)BENZENE manufacturer & supplier

Chemical Name:1,4-BIS(2-CHLOROETHYL)BENZENE

CAS.NO:7379-84-2

Synonyms:1,4-bis(2-chloroethyl)benzene

Molecular Formula:C₁₀H₁₂Cl₂

Molecular Weight:203.10800

HS Code:2903999090

Physical and Chemical Properties:

Melting point:46ºC

Boiling point:293.1ºC at 760 mmHg

Density:1.142g/cm3

Index of Refraction:1.531

PSA:

Exact Mass:202.03200

LogP:3.24920

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,4-bis(2-chloroethyl)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-bis(2-chloroethyl)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-bis(2-chloroethyl)benzene Use and application,1,4-bis(2-chloroethyl)benzene technical grade,usp/ep/jp grade.

Related News: The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. 1,4-BIS(2-CHLOROETHYL)BENZENE manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 1,4-BIS(2-CHLOROETHYL)BENZENE supplier Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData��s Company Financials database. 1,4-BIS(2-CHLOROETHYL)BENZENE vendor Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. 1,4-BIS(2-CHLOROETHYL)BENZENE factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).